| Bioactivity | Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC50=1 nM). Sotuletinib (BLZ945) dihydrochloride induces tumor cell apoptosis and effectively inhibits tumor growth in mouse models. Sotuletinib dihydrochloride can be used in cancer and amyotrophic lateral sclerosis (ALS) research[1]. |
| Target | IC50: CSF1-R (1 nM). |
| Name | Sotuletinib dihydrochloride |
| CAS | 2222138-40-9 |
| Formula | C20H24Cl2N4O3S |
| Molar Mass | 471.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013 Oct;19(10):1264-72. [2]. Pognan F, et al. Liver enzyme delayed clearance in rat treated by CSF1 receptor specific antagonist Sotuletinib. Curr Res Toxicol. 2022 Oct 29;3:100091. |
Sotuletinib dihydrochloride
CAS: 2222138-40-9 F: C20H24Cl2N4O3S W: 471.40
Sotuletinib (BLZ945) dihydrochloride is an orally active and blood-brain barrier-permeable CSF1-R-specific inhibitor (IC
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.